AZN icon

AstraZeneca

66.60 USD
-0.31
0.46%
At close Jan 17, 4:00 PM EST
After hours
66.68
+0.08
0.12%
1 day
-0.46%
5 days
1.09%
1 month
-0.86%
3 months
-14.64%
6 months
-16.50%
Year to date
1.09%
1 year
0.53%
5 years
29.75%
10 years
85.57%
 

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

Employees: 89,900

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

45% more call options, than puts

Call options by funds: $490M | Put options by funds: $338M

27% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 88

23% more repeat investments, than reductions

Existing positions increased: 489 | Existing positions reduced: 399

1% more funds holding

Funds holding: 1,197 [Q2] → 1,206 (+9) [Q3]

1.8% less ownership

Funds ownership: 33.26% [Q2] → 31.46% (-1.8%) [Q3]

5% less capital invested

Capital invested by funds: $40.2B [Q2] → $38B (-$2.21B) [Q3]

11% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 16 (-2) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for AZN.

Financial journalist opinion

Based on 331 articles about AZN published over the past 30 days

Neutral
Accesswire
7 hours ago
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=123954&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
Neutral
GlobeNewsWire
8 hours ago
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman
SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company's prospects in a critical market, triggering a securities class action lawsuit in the United States.
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman
Positive
Zacks Investment Research
8 hours ago
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
Neutral
Accesswire
9 hours ago
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=123948&wire=1 or contact Joseph E. Levi, Esq.
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN
Neutral
Accesswire
12 hours ago
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=123918&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
Neutral
Accesswire
12 hours ago
AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.
AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
13 hours ago
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=123883&wire=1 or contact Joseph E. Levi, Esq.
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Neutral
Accesswire
14 hours ago
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ:AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
Neutral
Accesswire
16 hours ago
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=123775&wire=1 or contact Joseph E. Levi, Esq.
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
Neutral
Accesswire
16 hours ago
AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").
AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Charts implemented using Lightweight Charts™